Sarcopenia – European Clinical Trials Information Network

Evaluation of nandrolone decanoate treatment combined with physiotherapy and diet in elderly patients with sarcopenia

Thu, 30 Apr 2026 13:07:55 +0000

This study focuses on sarcopenia, a condition characterized by the loss of muscle mass and function that typically develops with age. This condition can lead to difficulties in performing daily activities, increased risk of falls, and reduced quality of life in older adults. The study will evaluate a treatment combining nandrolone decanoate (also known as Deca-Durabolin) with comprehensive physical therapy and dietary modifications.

The research aims to determine how effective nandrolone therapy is in treating sarcopenia when combined with exercise and diet. During the study, participants will receive either intramuscular injections of nandrolone or a placebo, along with physical therapy and dietary guidance. The treatment period will last for 12 months.

The study will measure improvements in physical fitness through walking tests and other physical performance measures. This research is particularly important for understanding how to better manage muscle loss in older adults and potentially improve their overall function and independence in daily activities.

Evaluation of BIO-101 versus placebo for treating severe sarcopenia in elderly patients with reduced mobility

Wed, 29 Apr 2026 15:07:14 +0000

This study focuses on sarcopenia, a condition that causes loss of muscle mass and strength in elderly people. The research evaluates a new medication called BIO101 (also known as 20-hydroxyecdysone) in elderly patients who have severe sarcopenia and experience difficulty with movement. The purpose is to determine if this treatment can help prevent major mobility disability in older adults who are still able to live independently but are experiencing declining physical function.

During the study, participants will receive either BIO101 capsules at a dose of 700 milligrams per day (divided into two daily doses) or placebo capsules. The treatment will continue for up to 36 months. The medication is taken by mouth, and the study will monitor how well participants maintain their ability to move around and perform daily activities.

The research will measure several aspects of physical function, including walking speed, hand grip strength, and overall quality of life related to muscle strength. These measurements will help determine if the medication is effective in maintaining mobility and strength in elderly people with sarcopenia. The study is designed to be double-blind, which means neither the participants nor the researchers directly working with them will know who is receiving the actual medication or the placebo.

Study on Muscle Growth in Healthy Aging and Sarcopenia Patients Using Testosterone Undecanoate and Placebo

Wed, 29 Apr 2026 15:05:35 +0000

This clinical trial is focused on understanding how human muscles might remember past exposure to testosterone, a hormone important for muscle growth. The study is particularly interested in conditions like healthy aging and sarcopenia, which is the loss of muscle mass and strength as people age. The trial will also explore issues related to anabolic resistance, which is when muscles do not grow as expected in response to exercise or hormones, and anti-doping concerns in sports.

The study will use two treatments: Nebido, which contains testosterone undecanoate, and a placebo. Participants will be divided into groups, with some receiving the testosterone treatment and others receiving the placebo. The main goal is to see if muscles can grow back to their previous size and strength after stopping testosterone for a while. This will be compared between those who had testosterone before and those who did not.

Participants will undergo a series of tests to measure changes in muscle size, strength, and other characteristics. These tests will include methods like DEXA scans, which are used to measure body composition, and muscle biopsies, which involve taking a small sample of muscle tissue for analysis. The study will also look at how muscle cells change at a genetic level, including changes in DNA methylation, which is a process that can affect how genes are turned on or off. The trial aims to provide insights into how muscles respond to testosterone and how this might be used to improve muscle health in older adults.